Modelling Components
Risk Factors
CVD Prevention

CVD Prevention

Loading model...

This document describes two essential components of a disease modeling approach: how risk groups are defined and calculated, and how interventions modify incidence. The explanations focus on conceptual processes and logic without referencing specific code. ## Used in

CVD prevention strategies are incorporated as a risk factor in the following disease models:

Mechanism

1. Risk Group Definitions and Calculations

  1. Identification of Risk Factors
    The model uses demographic and epidemiological inputs to establish distributions for multiple factors such as systolic blood pressure, cholesterol levels, body mass index, and smoking status. These factors are considered simultaneously for each age and sex category.

  2. Population Sampling
    A correlated sampling method generates plausible joint values for the risk factors within each subgroup. This step captures how risk factors vary together at the population level.

  3. Threshold-Based Assignment
    Each simulated individual is assigned to a risk group based on the WHO PEN risk charts if relevant risk factors exceed predefined cut points. One factor surpasses a threshold. Multiple factors can surpass thresholds as well. Examples include:

    • Total cardiovascular risk under 10%
    • Total cardiovascular risk from 10% to 20% combined with systolic blood pressure above 140
    • Total cardiovascular risk above 20% combined with systolic blood pressure above 130
  4. Prevalence in Each Group
    After assignment, the model determines the fraction of the population in each risk group. These fractions are stored and used for subsequent calculations, including incidence estimation and intervention effects.


2. Incidence Modification Through Interventions

  1. Coverage Dynamics
    Each intervention has a baseline coverage and a target coverage. The population in need is identified by age, sex, and relevant risk factors. Coverage moves from baseline to target over a defined timescale.

  2. Impact Factor
    An intervention includes a percentage impact that lowers incidence among individuals who receive it. For example, "Prevention of SBP 140 TR 20" applies a specific reduction to individuals with systolic blood pressure above 140 and total risk above 20%. This impact factor is a measurable fraction by which the intervention decreases the transition into disease.

  3. Population Reached
    The coverage fraction is multiplied by the population in need to calculate how many individuals actually receive the intervention. Incidence for those reached is then adjusted by the specified impact factor.

  4. Adjustment of Incidence
    The baseline incidence for a risk group is modified according to coverage and impact. A typical calculation involves a multiplicative step that lowers the original incidence:

    new incidence = baseline incidence × (1 - (impact factor × coverage))

Interventions

CVD Interventions in Appendix 3

CategoryCodeName
Cardiovascular diseasesCV1Pharmacological treatment of hypertension in adults using either of the following: ACE-I; ARB; CCB. Single pill combination containing either of the following: ACE-I/CCB; ACE-I/Diuretic; ARB/CCB; ARB/Diuretic
Cardiovascular diseasesCV2aDrug therapy to control CVD risk using a total risk* approach and counselling to individuals who have had a heart attack or stroke and to persons with high risk (≥ 20%) of a fatal and non-fatal cardiovascular event in the next 10 years using the updated WHO CVD risk charts
Cardiovascular diseasesCV2bDrug therapy to control CVD risk using a total risk* approach and counselling to individuals who have had a heart attack or stroke and to persons with high risk (≥ 10%) of a fatal and non-fatal cardiovascular event in the next 10 years using the updated WHO CVD risk charts
Cardiovascular diseasesCV3aTreatment new cases of acute myocardial infarction with aspirin, initially treated in a hospital setting with follow-up carried out through primary health care facilities at a 95% coverage rate
Cardiovascular diseasesCV3bTreatment of new cases of acute myocardial infarction with aspirin and thrombolysis, initially treated in a hospital setting with follow-up carried out through primary health care facilities at a 95% coverage rate
Cardiovascular diseasesCV3cTreatment new cases of acute myocardial infarction with thrombolysis, aspirin and clopidogrel, initially treated in a hospital setting with follow-up carried out through primary health care facilities at a 95% coverage rate
Cardiovascular diseasesCV3dTreatment of new cases of myocardial infarction with primary percutaneous coronary interventions (PCI), aspirin and clopidogrel, initially treated in a hospital setting with follow-up carried out through primary health care facilities at a 95% coverage rate
Cardiovascular diseasesCV4aTreatment of acute ischemic stroke with intravenous thrombolytic therapy
Cardiovascular diseasesCV4bTreatment of acute ischemic stroke with mechanical thrombectomy within an experienced facility
Cardiovascular diseasesCV5aPrimary prevention of rheumatic fever and rheumatic heart diseases by increasing appropriate treatment of streptococcal pharyngitis at the primary care level
Cardiovascular diseasesCV5bSecondary prevention of rheumatic fever and rheumatic heart disease by developing a register of patients who receive regular prophylactic penicillin
Cardiovascular diseasesCV6Low-dose acetylsalicylic acid within 24 to 48 hours for secondary prevention of ischemic stroke
Cardiovascular diseasesCV7Comprehensive care of acute stroke patients in stroke units
Cardiovascular diseasesTreatment of congestive cardiac failure with angiotensin-converting-enzyme inhibitor, beta-blocker and diuretic
Cardiovascular diseasesCardiac rehabilitation post myocardial infarction
Cardiovascular diseasesAnticoagulation for medium-and high-risk non-valvular atrial fibrillation and for mitral stenosis with atrial fibrillation

Assumptions

No data to display.